What Auditors Look for in Your Visual Inspection Program: Avoiding Common 483 Observations

The Auditor's Perspective

When an FDA investigator or EU GMP inspector evaluates your visual inspection program, they are not looking for perfection — they are looking for a scientifically sound, well-documented system that demonstrates control. They want evidence that you understand your process, have qualified it appropriately, monitor it continuously, and respond to deviations with proper investigation and corrective action.

The most common inspection failures are not technical — they are documentation and program design gaps that suggest a lack of systematic control. Understanding what auditors examine allows you to build your program correctly from the start, rather than scrambling to remediate after a 483 observation. — [21 CFR Part 211; EU GMP Annex 1, 2022]

Top 10 FDA 483 Observations for Visual Inspection

Based on published FDA inspection data and industry experience, these are the most frequently cited observations:

1. Failure to establish adequate inspection procedures — SOPs lack specificity on conditions, timing, technique, or acceptance criteria
2. Inadequate inspector qualification/training documentation — Missing records, undefined acceptance criteria, or no formal qualification study
3. Failure to investigate AQL failures — Lots failed AQL but were reinspected and released without root cause investigation — [21 CFR 211.192]
4. Inadequate lighting conditions — Light intensity not within 2,000–3,750 lux or not periodically verified with calibrated meters — [USP <790>, 2016]
5. No periodic requalification of inspectors — Initial qualification exists but no defined requalification frequency or triggers
6. Defect test sets not maintained or characterized — Expired sets, uncharacterized defects, or sets that no longer represent current product defects
7. Inadequate trending of inspection data — No statistical process control, no alert/action limits, no evidence of continuous monitoring
8. Failure to validate automated inspection systems — AVI in use without complete IQ/OQ/PQ or without ongoing performance verification
9. Incomplete documentation of inspection activities — Missing batch records, unsigned forms, or gaps in data trails
10. No formal defect classification system — No documented criteria for critical/major/minor classification

The FDA Draft Guidance (2021) emphasizes that meeting USP compendial standards alone is NOT sufficient for CGMP compliance. A holistic, risk-based approach spanning development, production, inspection, and post-market surveillance is required. — [FDA Draft Guidance, 2021]

What Auditors Examine: The Documentation Trail

Standard Operating Procedures

Auditors will review your SOPs for specificity and completeness. They expect to find:

• Defined inspection conditions (lux range, background colors, viewing distance, inspection time per unit)
• Step-by-step inspection technique (swirling method, sequence of backgrounds, what to look for)
• Defect classification system with visual examples
• Accept/reject decision criteria
• AQL sampling procedures including switching rules
• Deviation and investigation procedures for AQL failures

Training and Qualification Records

For each active inspector, auditors expect:

• Current vision test results (20/20 acuity, color deficiency screening) — [USP <1790>, 2017]
• Initial training records with dates, topics, and trainer identification
• Qualification study data (Knapp test results with raw data, not just pass/fail)
• Pre-defined acceptance criteria (documented before the study, not adjusted afterward)
• Requalification records at defined intervals
• Evidence of product-specific training for each product type inspected

Equipment and Environmental Records

• Light meter calibration certificates (traceable to national standards)
• Periodic light intensity verification records at the inspection point
• For AVI/SAVI: IQ/OQ/PQ documentation, change control records, periodic challenge results
• Maintenance records for inspection equipment
• Environmental monitoring data for the inspection area

Batch-Level Records

• 100% inspection results: total inspected, total rejected, reject rate by category
• AQL sampling results: sample size, defects found, lot disposition decision
• Inspector identification for each batch
• Any deviations or investigations associated with the batch
• For AVI: system parameters used, any recipe changes, alarm events

EU GMP Annex 1 Specific Expectations

The 2022 revision introduced additional expectations that EU auditors now verify:

• CCS integration: Visual inspection must be documented as part of your Contamination Control Strategy — [EU GMP Annex 1, Section 8.20, 2022]
• Risk-based justification: Your inspection approach (method, extent, acceptance criteria) must be justified through documented risk assessment
• Section 8.32 compliance: Qualification of inspection processes, including challenge testing for automated systems. Note: BioPhorum has highlighted potential confusion in interpreting this section — ensure your approach is clearly documented and defensible — [BioPhorum, PDA Letter, March 2024]
• Container closure integrity: Auditors will verify that visual inspection and CCI testing are integrated and that you understand what each method covers

Preparing for an Audit

Proactive preparation is far more effective than reactive remediation:

1. Self-audit annually: Walk through your program as an auditor would — check every document, verify every record, test every claim in your SOPs
2. Verify test set currency: Ensure defect test sets are within their characterized shelf life and include all relevant defect types for current products
3. Confirm all inspectors are current: Check that vision tests, qualifications, and requalifications are up to date for every active inspector
4. Review trending data: Ensure you can demonstrate continuous monitoring with defined alert and action limits
5. Check investigation completeness: Every AQL failure should have a documented investigation with root cause, CAPA, and effectiveness verification — [21 CFR 211.192; ICH Q10, 2008]
6. Validate your AVI (if applicable): Confirm ongoing performance verification is current and that any recipe changes went through change control

The "Why" Behind Each Requirement

Understanding the regulatory intent helps you build a program that satisfies the spirit — not just the letter — of the requirements:

• Inspector qualification exists because visual inspection is subjective — you must prove your people can actually detect defects at acceptable rates
• AQL sampling exists because 100% inspection is imperfect — you need statistical verification that your process is working
• Trending exists because processes drift — without monitoring, you won't know when performance degrades until a patient is harmed
• Investigation requirements exist because failures contain information — understanding why a lot failed prevents recurrence
• Documentation exists because "if it isn't documented, it didn't happen" — regulators cannot verify what isn't recorded

A program built on this understanding will naturally satisfy auditors because it demonstrates genuine process control rather than paper compliance.

References

1. 21 CFR Part 211, "Current Good Manufacturing Practice for Finished Pharmaceuticals."
2. FDA Draft Guidance, "Inspection of Injectable Products for Visible Particulates," December 2021.
3. USP General Chapter <790>, "Visible Particulates in Injections," 2016.
4. USP General Chapter <1790>, "Visual Inspection of Injections," 2017.
5. EU GMP Annex 1, "Manufacture of Sterile Medicinal Products," August 2022.
6. BioPhorum, "A View on the Revised Annex 1: Requirements on Visual Inspection Processes," PDA Letter, March 2024.
7. ICH Q10, "Pharmaceutical Quality System," 2008.
8. 21 CFR 211.192, "Production record review."